VetOncoRx on the cutting edge of Canine Cancer Research
VetOncoRx is a biopharmaceutical company that focuses on the treatment of canine cancers, including hemangiosarcoma, melanoma and osteosarcoma. VetOncoRx is taking preclinical drugs for humans and adapting them to treat the corresponding affliction in dogs. VetOncoRx is working side by side with the Animal & Veterinary branch of the FDA for preclinical development and, ultimately, clinical approval of first-in-class molecular targeted cancer therapeutics in dogs. Our drug candidates target a translation initiation factor that is responsible for uncontrolled growth in a multitude of mammalian cancers. These innovative drugs for dogs are designed to block cancer growth and inhibit disease progression while producing fewer side effects. VetOncoRx will revolutionize canine treatment options where there is currently a huge void in available therapeutics.